Immune Suppression and Colorectal Cancer

C. Evans; A. G. Dalgleish; D. Kumar


Aliment Pharmacol Ther. 2006;24(8):1163-1177. 

In This Article

Complement Decay Accelerating Factor, CD55

In addition to the above, colorectal tumours express CD55 which is a ligand that protects against complement-induced cell death and its overexpression is significantly associated with reduced survival.[212] An anti-idiotype vaccine against this epitope has shown encouraging results in that it can induce strong T and NK cell immune responses; however, early results suggesting clinical activity were not confirmed in a randomized study which used more advanced patients.[213] Studies in early stage disease would be more appropriate.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: